April 13, 2021
1 min learn
Butt experiences no related monetary disclosures. Please see the examine for all different authors’ related monetary disclosures.
Dapagliflozin is equally as efficient in ladies as in males in lowering threat for worsening HF, CV loss of life and all-cause loss of life in contrast with placebo, in keeping with new information from the DAPA-HF trial.
“Dapagliflozin diminished the chance of worsening coronary heart failure and loss of life and improved signs, bodily perform and health-related high quality of life equally in women and men with coronary heart failure and diminished ejection fraction,” Jawad H. Butt, MD, analysis fellow within the division of cardiology at Rigshospitalet at Copenhagen College Hospital in Denmark, and colleagues wrote.
As Healio previously reported, in the principle outcomes of DAPA-HF, dapagliflozin (Farxiga, AstraZeneca) diminished threat for worsening HF and CV loss of life when added to straightforward remedy in sufferers with HFrEF no matter whether or not they had diabetes.
For the present examine, researchers analyzed 4,744 sufferers (23.4% ladies) with HFrEF.
Researchers discovered that dapagliflozin diminished threat for worsening HF or CV loss of life in contrast with placebo equally in women and men (HR in males = 0.73; 95% CI, 0.63-0.85; HR in ladies = 0.79; 95% CI, 0.59-1.06; P for interplay = .67).
The remedy impact of dapagliflozin was comparable in each sexes for all secondary outcomes, together with all-cause loss of life, Butt and colleagues wrote.
In accordance with the researchers, in contrast with males, ladies had decrease threat for worsening HF or CV loss of life (adjusted HR = 0.72; 95% CI, 0.61-0.85) and worsening HF, CV loss of life and episodes of outpatient worsening (aHR = 0.8; 95% CI, 0.69-0.92).
“Girls had a decrease threat of those outcomes in contrast with males, even after adjustment for different prognostic variables, together with left ventricular EF and N-terminal pro-B-type natriuretic peptide,” Butt and colleagues wrote.
In each sexes, dapagliflozin in contrast with placebo elevated the proportion of sufferers with meaningfully improved signs and decreased the proportion with worsening signs, in keeping with the researchers.
“These findings present additional assist for dapagliflozin as a brand new remedy possibility for sufferers with HFrEF,” the researchers wrote.